Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immune Checkpoint Inhibitor-Related Cytopenias: About 68 Cases from the French Pharmacovigilance Database.
Martin M, Nguyen HM, Beuvon C, Bene J, Palassin P, Atzenhoffer M, Rouby F, Sassier M, Pérault-Pochat MC, Roblot P, Allouchery M, Puyade M; French Network of Regional Pharmacovigilance Centers. Martin M, et al. Among authors: atzenhoffer m. Cancers (Basel). 2022 Oct 14;14(20):5030. doi: 10.3390/cancers14205030. Cancers (Basel). 2022. PMID: 36291814 Free PMC article.
Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer.
Allouchery M, Lombard T, Martin M, Rouby F, Sassier M, Bertin C, Atzenhoffer M, Miremont-Salame G, Perault-Pochat MC, Puyade M; French Network of Regional Pharmacovigilance Centers. Allouchery M, et al. Among authors: atzenhoffer m. J Immunother Cancer. 2020 Dec;8(2):e001622. doi: 10.1136/jitc-2020-001622. J Immunother Cancer. 2020. PMID: 33428586 Free PMC article.
Immune-related generalised oedema - A new category of adverse events with immune checkpoint inhibitors.
Velev M, Baroudjian B, Pruvost R, De Martin E, Laparra A, Babai S, Teysseire S, Danlos FX, Albiges L, Bernigaud C, Benderra MA, Pradère P, Zaidan M, Decroisette C, Fallah F, Matergia G, Lavaud P, Jantzem H, Atzenhoffer M, Buyse V, Ammari S, Robert C, Champiat S, Messayke S, Marabelle A, Guettier C, Lebbe C, Lambotte O, Michot JM. Velev M, et al. Among authors: atzenhoffer m. Eur J Cancer. 2023 Jan;179:28-47. doi: 10.1016/j.ejca.2022.11.001. Epub 2022 Nov 12. Eur J Cancer. 2023. PMID: 36473326
[COVID-19 and adenovirus vaccines: French experience of enhanced pharmacovigilance].
Massy N, Atzenhoffer M, Boulay C, Pecquet PE, Ledys F, Cracowski JL, Masmoudi K, Lepelley M, Gras-Champel V. Massy N, et al. Among authors: atzenhoffer m. Therapie. 2023 Sep-Oct;78(5):489-498. doi: 10.1016/j.therap.2023.01.005. Epub 2023 Jan 21. Therapie. 2023. PMID: 36759287 Free PMC article. French.
Nirmatrelvir/ritonavir (Paxlovid®): French pharmacovigilance survey 2022.
Bihan K, Lipszyc L, Lemaitre F, Dautriche A, Fédrizzi S, Atzenhoffer M, Vitores A, Page A, Lebrun-Vignes B. Bihan K, et al. Among authors: atzenhoffer m. Therapie. 2023 Sep-Oct;78(5):531-547. doi: 10.1016/j.therap.2023.03.001. Epub 2023 Mar 7. Therapie. 2023. PMID: 37012153 Free PMC article.
Monitoring the safety of drugs and COVID-19 vaccines by the French Pharmacovigilance Centers during the pandemic: A win-win bet with Health Authorities!
Jonville-Bera AP, Gautier S, Micallef J, Massy N, Atzenhoffer M, Grandvuillemin A, Drici MD; French Network of Regional Pharmacovigilance Centres. Jonville-Bera AP, et al. Among authors: atzenhoffer m. Therapie. 2023 Sep-Oct;78(5):467-475. doi: 10.1016/j.therap.2023.03.002. Epub 2023 Mar 7. Therapie. 2023. PMID: 37012154 Free PMC article.
Drug-Induced Uveitis Related to Checkpoint Inhibitors and MAP-kinase Inhibitors.
Thibault T, Ben Ghezala I, Freppel R, Rajillah A, Boulay C, Brunel P, Atzenhoffer M, Auvens C, Devilliers H, Grandvuillemin A. Thibault T, et al. Among authors: atzenhoffer m. Ophthalmology. 2024 Feb;131(2):249-251. doi: 10.1016/j.ophtha.2023.10.004. Epub 2023 Oct 10. Ophthalmology. 2024. PMID: 37820932 No abstract available.
19 results